Validea Detailed Fundamental Analysis

Validea's guru fundamental report assigned McKesson Corp (MCK), a large-cap growth stock in the Major Drugs industry, a 100% rating from Pim van Vliet's Multi-Factor Investor model. This model seeks low volatility stocks with strong momentum and high net payout yields, with the perfect score indicating strong interest based on MCK's underlying fundamentals and valuation. The rating suggests MCK aligns well with a strategy focused on potentially outperforming low-volatility assets while managing risk.

Analysis

McKesson Corp (MCK) has received a perfect 100% rating from Validea's Multi-Factor Investor model, which is based on the quantitative strategy of Pim van Vliet. This model identifies attractive investments by screening for a combination of low volatility, strong momentum, and high net payout yield. The perfect score indicates a strong alignment with this conservative, factor-based approach. Specifically, MCK passed the model's criteria for market capitalization and standard deviation, confirming its low-volatility characteristic, which is the cornerstone of van Vliet's thesis. However, the report also notes that MCK's 'Twelve Minus One Momentum' and 'Net Payout Yield' were rated as neutral. The fact that MCK achieved a top final rank despite these neutral signals suggests that its low-risk profile is weighted heavily enough within the model to overcome the lack of strong momentum or immediate high shareholder yield, positioning it as a prime example of the 'low-risk anomaly' in the large-cap Major Drugs industry.

Key Decisions for Investors

• Investors utilizing low-volatility or factor-based strategies should consider this 100% rating a significant positive quantitative signal for McKesson Corp.
• Given the neutral ratings for momentum and net payout yield, it is prudent to monitor these specific metrics, as any positive shift could provide an additional catalyst for the stock.
• This analysis is based on a specific quantitative model; therefore, this positive screen should be supplemented with fundamental analysis of MCK's operational performance and the broader outlook for the pharmaceutical distribution industry.